Applications
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Application in Safety Prediction & Dose Ranging
Are you currently facing complex clinical trials, long drug development cycles, and high IND failure rates? Our Integrated Preclinical Solutions help you streamline clinical trial processes, reduce IND failure risk, and ensure patient safety through advanced new approach methodologies and Gold-Standard NHP Studies.
Creative Biolabs' NHP De-risk Your Biologic Development Path!
NHP models provide essential translational safety and PK/PD data required for IND-enabling studies, directly mitigating risks in first-in-human (FIH) trials.
Overview of NHP Applications
What Are Our Research Areas?
The development of novel biologics, including mAbs, bi-specifics, and advanced cell and gene therapies, demands highly predictive preclinical safety and dose-ranging strategies. Drug developers must accurately assess a therapeutic's pharmacokinetic profile (what the body does to the drug), its pharmacodynamic effect (what the drug does to the body), and its potential toxicology before advancing to clinical trials. NHP models are uniquely positioned to address this need, particularly when target-related toxicity is complex or when non-animal-based advanced new approach methodologies require in vivo translational context. The ultimate goal is to generate a comprehensive, regulatory-compliant data package to select the optimal and safest FIH dose.
Why Choose Us?
NHPs remain the gold standard for preclinical assessment of many biologics due to key biological similarities with humans. Creative Biolabs leverages these advantages to maximize data quality and translational relevance:
- Genetic and Immunological Similarities: NHPs possess high homology in drug target expression, receptor occupancy, and immune system function compared to small animal models, offering the most relevant model for predicting human immunotoxicity and immune-related adverse events.
- Clinical Translational Relevance: NHP data on dose-exposure-response relationships (PK/PD) are directly scalable to humans, supporting robust and scientifically justified FIH dose calculations, often leveraging Quantitative Systems Pharmacology (QSP) models.
- Data Types Required for Regulatory Submissions: NHP nonclinical toxicity data—especially for repeat-dose studies and complex therapies like gene therapies—are frequently mandatory by global Drug Regulatory Authorities for IND applications.
Distributed under Unsplash License, from Unsplash.
Key Applications
NHPs allow for the precise characterization of novel therapeutics in the most relevant in vivo context. Creative Biolabs utilizes NHP models to provide highly specific data across critical development areas:
- Dose-Range Finding and FIH Dose Selection: NHP models are used to define the non-toxic dose range and characterize the exposure-response relationship, directly informing the initial safe dose for clinical trials. This is crucial for next-generation engineered proteins where unique PK/PD profiles dictate safety margins.
- Target-Mediated Toxicity Assessment and Immunotoxicity: NHPs are used to evaluate target-specific adverse events—particularly for oncology mAbs with Well-Characterized Targets—by monitoring the specific tissue distribution and functional effects of the drug. They are also indispensable for characterizing the risk of unwanted immune responses, such as ADA and CRS.
- PK and TK Profiling: Providing detailed single and multiple-dose PK/TK profiles required for regulatory submission, translate in vivo NHP exposure to predicted human exposure, justifying the clinical protocol.
- Advanced Therapy Safety and Biodistribution: For complex modalities like Gene Therapy Vectors, NHPs are required to track vector biodistribution and persistence across various organs, which is a key safety requirement for all IND submissions in this space.
How Do Creative Biolabs Support Your Projects?
Creative Biolabs provides an integrated suite of services to support your preclinical NHP strategy, from initial specimen collection to advanced modeling and regulatory report generation. Our service capabilities are mapped to your development needs:
| Service Capability | Corresponding Application Area |
| DMPK & PK/PD Evaluation | FIH Dose Selection & PK/TK Profiling |
| Safety & Toxicology | Target-Mediated Toxicity & Regulatory Compliance |
| Bioanalysis & Biomarker | TMT, Immunogenicity & Mechanistic Readouts |
| Pharmacology & Efficacy | Disease Modeling & Efficacy Proof-of-Concept |
Translational Impact
Leveraging NHP models with advanced analytical and modeling support is the most effective way to validate your therapeutic hypothesis and de-risk the transition to the clinic. At Creative Biolabs, we focus on providing data that directly translates to improved patient safety and regulatory success. Our clients consistently see a reduction in the risk of IND clinical holds by incorporating comprehensive NHP safety and PK/PD data packages informed by our strategic guidance.
Frequently Asked Questions
Q: What is the turnaround time for a standard NHP repeat-dose toxicology study, and what data format is provided?
A: Turnaround time is primarily dependent on the study duration (e.g., 1-month or 3-month) and the complexity of the endpoints. We prioritize clear communication and provide clients with a detailed project timeline upfront. The final data package includes integrated PK/TK, safety, and pathology reports, delivered in formats that align directly with global regulatory submission requirements.
Q: How does your service address the high immunogenicity risk associated with novel engineered bi-specific antibodies or ADCs in NHPs?
A: For complex, next-generation biologics like bi-specifics, we deploy specialized assays for immunogenicity assessment. This includes highly sensitive ADA assays and Neutralizing Antibody (NAb) assays in NHP serum. Furthermore, we use Receptor Occupancy (RO) and Flow Cytometry to mechanistically characterize target engagement and potential immune cell activation, providing comprehensive data to mitigate clinical immunogenicity risk.
Q: What sample types can be collected for customized analysis during an NHP study, and how is sample stability maintained?
A: Our Biological Collection & Biobanking services allow for custom collection of a vast array of high-quality biospecimens, including Blood, Serum, Plasma, PBMCs, CSF, and FFPE/Frozen Tissue Panels. We utilize a rigorous, validated cold-chain transportation and sample management system (including standardized labeling and aliquoting) to ensure sample integrity and stability from collection through to final bioanalysis.
Contact Us
Creative Biolabs provides the industry's most robust platform for NHP Applications in Safety Prediction & Dose Ranging, ensuring your therapeutic candidates transition safely and efficiently into the clinic. Reach out to our expert team today to discuss how our gold-standard NHP studies can accelerate your IND submission and reduce translational risk.